We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




Blood-Brain Barrier Opening Device Enables Liquid Biopsy Tests in Brain Tumor Patients

By HospiMedica International staff writers
Posted on 27 Oct 2023

The blood-brain barrier (BBB) serves as a protective shield for the brain, strictly controlling the substances that can move from the bloodstream into the brain. More...

This barrier not only keeps harmful molecules at bay but also limits the reach of potentially beneficial drugs and diagnostic markers, thus preventing measurement using a blood test. Now, a non-invasive medical device that reversibly opens the BBB exactly where it is needed can pave the way for precision medicine, delivering drugs, and measuring circulating biomarkers via a blood test to diagnose and track brain diseases.

Cordance Medical (Mountain View, CA, USA) has developed the NeuroAccess device aimed at adults aged 22 and older who have known or suspected brain tumors. The device allows healthcare experts to non-invasively raise the levels of cell-free DNA (cfDNA) in the bloodstream, enhancing the performance of liquid biopsies for oncology. The device employs focused ultrasound coupled with microbubbles to safely and temporarily open the BBB. With its portable design, the goal is for the NeuroAccess device to be used for SonoBiopsy procedures in various healthcare settings, from community clinics to hospitals.

Earlier in the year, initial studies confirmed the safety and feasibility of using the SonoBiopsy technique in patients with brain tumors. Previous research using focused ultrasound and microbubbles to open the BBB has shown promise for treating various neurological conditions, such as glioblastoma, brain metastasis, Alzheimer's, and Parkinson's. Now, the U.S. Food and Drug Administration has given the NeuroAccess device a Breakthrough Device Designation, indicating its transformative potential for meeting the medical needs of brain tumor patients by offering a safer way to obtain molecular characterization of their tumors.

"This Breakthrough Device Designation from the FDA is a pivotal milestone for Cordance Medical and for patients requiring more efficacious diagnostic solutions," said Ryan Dittamore, CEO of Cordance Medical. "We are keen to continue our clinical trials and to collaborate closely with the FDA to bring this groundbreaking technology to market."

Related Links:
Cordance Medical 


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Infusion System
SIGMA Spectrum
New
Sling
GoComfort
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The engine-free, nonlinear, flexible, micro-robotic platform leverages AI to optimize GBM treatment (Photo courtesy of Symphony Robotics)

First-Ever MRI-Steerable Micro-Robotics to Revolutionize Glioblastoma Treatment

Glioblastoma Multiforme (GBM) is one of the most aggressive and difficult-to-treat brain cancers. Traditional surgical procedures, such as craniotomies, involve significant invasiveness, requiring large... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.